1786438-30-9

1786438-30-9 structure

Name: (R)-CR8
Chemical Name: (R)-CR8 trihydrochloride
CAS Number: 1786438-30-9
Molecular Formula: C₂₄H₃₂Cl₃N₇O
Molecular Weight: 540.92
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2020-01-23 10:55:51
Modify Date: 2025-08-26 17:21:44
(R)-CR8 trihydrochloride (CR8 trihydrochloride), a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect[1][2].

Name	(R)-CR8 trihydrochloride

Description	(R)-CR8 trihydrochloride (CR8 trihydrochloride), a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> CDK Research Areas >> Neurological Disease
Target	CDK1/cyclinB1:0.09 μM (IC50) cdk2/cyclin A:0.072 μM (IC50) CDK2/cyclinE:0.041 μM (IC50) Cdk5/p25:0.11 μM (IC50) CDK7/cyclin H:1.1 μM (IC50) CDK9/Cyclin T:0.18 μM (IC50) CK1δ/ε:0.4 μM (IC50)
In Vitro	(R)-CR8 trihydrochloride (CR8 trihydrochloride) (0.1-100 μM; 48 hours) is a potent inducer of apoptotic cell death with an IC50 of 0.49 μM for SH-SY5Y cell line[1]. (R)-CR8 trihydrochloride (0.25-10 μM) induces a dose-dependent induction of poly-(ADP-ribose)polymerase (PARP) cleavage[1]. Apoptosis Analysis[1] Cell Line: SH-SY5Y cell line Concentration: 0.1, 1, 10, 100 μM Incubation Time: 24 hours Result: Reduced cell survival in a dose-dependent manner.
In Vivo	(R)-CR8 trihydrochloride (5 mg/Kg; i.p.) results in a significant reduction in lesion size at 28 days in histological assessment[2]. Animal Model: Adult (10 to 12 weeks old) male Sprague-Dawley rats (310 to 330 g)[2] Dosage: 5 mg/Kg Administration: i.p. Result: Resulted in a significant reduction in lesion size.
References	[1]. Bettayeb K, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. [2]. Kabadi SV, et al. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13.

Molecular Formula	C₂₄H₃₂Cl₃N₇O
Molecular Weight	540.92

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1786438-30-9	294646-77-8
1956437-40-3	73981-53-0
158749-75-8	1391515-37-9
122091-54-7	528566-21-4
1391519-06-4	1640848-93-6
915921-43-6	400866-46-8
892363-63-2	933984-78-2
247583-73-9	1196532-92-9
247583-68-2	936734-94-0
959927-41-4	1895301-34-4